59 results about "Nordihydroguaiaretic acid" patented technology

A method for preparing a nontoxic composition that includes an extract of Larrea tridentata plant material and is substantially free of nordihydroguaiaretic acid (NDGA) quinone includes the steps of mixing the Larrea tridentata plant material with an aqueous solvent to produce an extract, and reducing any NDGA quinone in the extract to NDGA. A method for treating an infection from a virus includes the step of administering to a human in need thereof a pharmaceutical composition comprising an extract of Larrea tridentata in an amount that is effective to suppress NF-kB activation. An antimicrobial solution includes an aqueous solvent, and an extract of Larrea tridentata plant material. A formulation for medical and health products includes an extract of Larrea tridentata plant material, and at least one detoxification enhancer that functions as a chemoprotective agent.

The present invention relates to the use of a combination of nordihydroguaiaretic acid and an aminoglycoside for treating a microbial infection or for killing clinically latent microorganisms associated with microbial infections.

A UGT2B inhibitor capable of increasing the bio-availability of a drug, is a compound in a free base or a pharmaceutically acceptable salt form that is selected from the group consisting of: capillarisin, isorhamnetin, β-naphthoflavone, α-naphthoflavone, hesperetin, terpineol, (+)-limonene, β-myrcene, swertiamarin, eriodictyol, cineole, apigenin, baicalin, ursolic acid, isovitexin, lauryl alcohol, puerarin, trans-cinnamaldehyde, 3-phenylpropyl acetate, isoliquritigenin, paeoniflorin, gallic acid, genistein, glycyrrhizin, protocatechuic acid, ethyl myristate, umbelliferone, PEG (Polyethylene glycol) 400, PEG 2000, PEG 4000, Tween 20, Tween 60, Tween 80, BRIJ® 58, BRIJ® 76, Pluronic® F68, Pluronic® F127, and a combination thereof. A UGT2B enhancer capable of enhancing a clearance rate of morphine-like analgesic agents, is a compound in a free base or a pharmaceutically acceptable salt form that is selected from the group consisting of: nordihydroguaiaretic acid, wogonin, trans-cinnamic acid, baicalein, quercetin, daidzein, oleanolic acid, homoorientin, hesperetin, narigin, neohesperidin, (+)-epicatechin, hesperidin, liquiritin, eriodictyol, formononetin, quercitrin, genkwanin, kaempferol, isoquercitrin, (+)-catechin, naringenin, daidzin, (−)-epicatechin, luteolin-7-glucoside, ergosterol, rutin, luteolin, ethyl myristate, apigenin, 3-phenylpropyl acetate, umbelliferone, glycyrrhizin, protocatechuic acid, poncirin, isovitexin, 6-gingerol, cineole, genistein, trans-cinnamaldehyde, and a combination thereof.

A cosmetic skin care composition includes salicylhydroxamate or one or more other hydroxamate derivatives in an amount of about 0.001% to about 10.0% by weight, and nordihydroguaiaretic acid or one or more other antioxidants in an amount of about 0.00001% to about 10% by weight. The composition can be optionally encapsulated in a liposomal vehicle.

The NF-E2-related factor 2 (Nrf2) is a key transcriptional regulator of antioxidant defense and detoxification. To directly monitor stabilization of Nrf2 we fused its Neh2 domain, responsible for the interaction with its nucleocytoplasmic regulator, Keap1, to firefly luciferase (Neh2-luciferase). It is shown herein that Neh2 domain is sufficient for recognition, ubiquitination and proteasomal degradation of Neh2-luciferase fusion protein. The novel Neh2-luc reporter system allows direct monitoring of the adaptive response to redox stress and classification of drugs based on the time-course of reporter activation. The novel reporter was used to screen a library of compounds to identify activators of Nrf2. The most robust and yet non toxic Nrf2 activators found—nordihydroguaiaretic acid, fisetin, and gedunin-induced astrocyte-dependent neuroprotection from oxidative stress via an Nrf2-dependent mechanism.

Compositions and methods for using nordihydroguaiaretic acid (NDGA) derivatives for preventing the expression of MDR-1 gene and the synthesis of PgP protein or reversing multiple drug resistance in cells, and for using NDGA derivatives in combination with additional chemotherapeutic agents to treat drug resistant cancer and infections.

Nordihydroguaiaretic acid derivatives and methods of use thereof for the treatment of tumors.

Nordihydroguaiaretic acid derivatives and methods of use thereof for the treatment of tumors.

Disclosed are nordihydroguaiaretic acid derivative compounds including various end groups bonded by a carbon atom or heteroatom though a side chain bonded to the respective hydroxy residue O groups by an ether bond or a carbamate bond, pharmaceutical compositions, methods of making them, and methods of using them and kits including them for the treatment of diseases and disorders, in particular, diseases resulting from or associated with a virus infection, such as HIV infection, HPV infection, or HSV infection, an inflammatory disease, such as various types of arthritis and inflammatory bowel diseases, a metabolic disease, such as diabetes, a vascular disease, such as hypertension and macular degeneration, or a proliferative disease, such as diverse types of cancers.

The invention relates to a method for preparing a cellularized biological valve material, which is characterized by comprising the following steps: performing cell removal treatment for a heart valve of a pig aorta, then using nordihydroguaiaretic acid solution to cross link, and performing post treatment after the cross linking. The concentration of the used cross linking agent is 0.1 to 10 mg / ml. The cross linking conditions comprise that the shake cross linking is carried out for 2 to 240 hours at 60 to 360rpm at the temperature of between 1 and 40 DEG C, then the heart valve is taken out and soaked into D-Hanks solution, and the heart valve is post-treated for 3 to 40 days at the temperature of between 1 and 6 DEG C so as to obtain the cellularized biological valve material. By adjusting the concentrations of the cross linking agent the nordihydroguaiaretic acid solution, the cross linking time, the cleaning time and the like, the adjustment and control in the aspects of cross linking mechanical strength, enzymolysis resistance, cross linking agent release, tissue regeneration capacity promotion and the like are realized.

Use of nordihydroguaiaretic derivatives to suppress CDC-2 and survivin, stimulate apoptosis, and treat tumors.

This invention is to provide multiple specific inhibitors of cytochrome P450 isozyme CYP2C9. These inhibitors can be derived from any combinations with the following compounds including: Tamarixetin, Formononetin, isoliquritigenin, Phloretin, luteolin, Quercitrin, quercetin, myricetin, Wongonin, Puerarin, Genistein, Nordihydroguaiaretic acid, Narigenin, Capillarisin, Chrysin, Fisefin, eriodictyol, 6-Gingerol, Isorhamneti, isoquercitrin, Morin, (+)-Taxifolin, isovitexin, 3-Phenylpropyl Acetate, Oleanolic acid, ursolic acid, β-Myrcene, cinnamic acid, Luteolin-7-Glucoside, Liquiritin, (+)Limonene, Homoorientin, Swertiamarin, Embelin, Daidzein, Poncirin, (−)-Epicatechin, ergosterol. These natural products can be used to enhance the bioavailability of therapeutic agents (drugs).

The present invention relates to nordihydroguaiaretic acid derivative compounds, namely, butane bridge modified nordihydroguaiaretic acid (NDGA) compounds and butane bridge modified tetra-O-substituted NDGA compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them and kits including them for the treatment of diseases and disorders, in particular, diseases resulting from or associated with a virus infection, such as HIV infection, HPV infection, or HSV infection, an inflammatory disease, such as various types of arthritis and inflammatory bowel diseases, metabolic diseases, such as diabetes and hypertension, or a proliferative disease, such as diverse types of cancers.

The present invention provides one kind of UGT2B inhibitor capable of raising the bioavailability of medicine. The UGT2B inhibitor is one or the composition of capillarisin, isorhamnetin, beta-naphthoflavone and other compounds and in the form of alkali or pharmaceutically acceptable salt. The present invention also provides one kind of UGT2B promoter capable of promoting the detoxication function of liver. The UGT2B promoter is one or the composition of nordihydroguaiaretic acid, wogonin, trans-cinnamicacid and other compounds and in the form of alkali or pharmaceutically acceptable salt.

The present invention relates to nordihydroguaiaretic acid derivative compounds, namely, butane bridge modified nordihydroguaiaretic acid (NDGA) compounds and butane bridge modified tetra-O-substituted NDGA compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them and kits including them for the treatment of diseases and disorders, in particular, diseases resulting from or associated with a virus infection, such as HIV infection, HPV infection, or HSV infection, an inflammatory disease, such as various types of arthritis and inflammatory bowel diseases, metabolic diseases, such as diabetes and hypertension, or a proliferative disease, such as diverse types of cancers.

The invention relates to the field of composite fertilizers for crops, and concretely relates to a special slow release composite fertilizer for sesame plantation. The composite fertilizer is prepared by using the raw materials, by weight, 20-25 parts of decomposed livestock and poultry night soil, 10-12 parts of rice husk, 10-12 parts of sorghum straw, 3-6 parts of wood chip, 0.1-0.2 parts of gypsum powder, 18-20 parts of ammonium hydrogen phosphate, 1-2 parts of amino acid powder, 30-35 parts of potassium dihydrogen phosphate, 8-10 parts of urea-formaldehyde resin, 35-40 parts of urea, 8-10 parts of ammonium chloride, 4-5 parts of sodium tetraborate, 1-3 parts of sodium silicate, 15-18 parts of perilla cake meal, 1-3 parts of bark of Debregeasia orientalis, 10-12 parts of sludge compost, 0.01-0.02 parts of nordihydroguaiaretic acid, 2-3 parts of tungoiltree seed shell, 0.02-0.05 parts of cellulase, 0.05-0.08 parts of an EM inoculant and 3-5 parts of an assistant. The slow release composite fertilizer enables nutrients to be adsorbed and coated, so the nutrients cannot be lost, the fertilizer effect is lasting, and the fertilizing rule accords with the fertilizer demanding rule of sesame growth; and contained active components can promote the absorption and utilization of the nutrients by the roots of sesame plants, so the plant growth is strong, the fruit ratio is high, grains are plump, and the yield and income increasing effect is obvious.

A method for detecting the content of four disabled components (aristolochic acid, salicylic acid, nordihydroguaiaretic acid and cinnamyl anthranilate) in flavors and fragrances comprises the steps of preparing a sample solution, performing liquid chromatogram analysis, calculating detected results and the like. After optimized, the method has the advantages of being short in detection time, simple and convenient to operate, high in sensitivity and recovery rate, good in repeatability and the like. The chromatographic condition of the method enables the aristolochic acid, the salicylic acid, the nordihydroguaiaretic acid and the cinnamyl anthranilate to be separated well, the method has good correlation, a detecting range is limited from 0.04mug to 0.34mug, the average recovery rates are respectively 94.01%, 95.96%, 86.48% and 84.28%, and average relative standard deviations of sample testing results are respectively 4.40%, 2.39%, 2.49% and 3.35%.

Use of nordihydroguaiaretic derivatives to suppress CDC-2 and survivin, stimulate apoptosis, and treat tumors.

Disclosed are nordihydroguaiaretic acid derivative compounds including various end groups bonded by a carbon atom or heteroatom though a side chain bonded to the respective hydroxy residue O groups by an ether bond or a carbamate bond, pharmaceutical compositions, methods of making them, and methods of using them and kits including them for the treatment of diseases and disorders, in particular, diseases resulting from or associated with a virus infection, such as HIV infection, HPV infection, or HSV infection, an inflammatory disease, such as various types of arthritis and inflammatory bowel diseases, a metabolic disease, such as diabetes, a vascular disease, such as hypertension and macular degeneration, or a proliferative disease, such as diverse types of cancers.

The invention discloses medicine of an erdosteine composition capsule for treating airway inflammation, and belongs to the technical field of medicine. The erdosteine composition capsule is prepared from erdosteine, starch, nordihydroguaiaretic acid, 95-percent ethanol, polyvidone K30 and talcum. The erdosteine is a novel crystal form compound; an X-ray powder diffraction pattern obtained through Cu-Ka ray measurement is shown as a Figure 1; the medicine belongs to the erdosteine different from that reported in the prior art. Experiments show that the erdosteine novel crystal form compound has better solubility and higher stability; the prepared capsule has high dissolution rate and good stability, and is very suitable for clinic application.

Disclosed herein are methods and compositions for the treatment of prostate cancer with an IGF-1 receptor kinase inhibitor. Methods are also provided for the treatment of prostate cancer by identifying a level of IGF-1 receptor expression and making a decision whether to treat with an IGF-1 receptor kinase inhibitor.

Provided herein are methods for inhibiting proliferation of a microbe associated with a sexually transmitted disease (STD) or infection and for preventing transmission of one or more sexually transmitted diseases in a subject at-risk for acquiring the same, including an HIV positive subject at risk for acquiring another sexually transmitted disease. The methods comprise contacting a microbe or cell thereof associated with the STD or administering to the subject nordihydroguaiaretic acid or a derivative or analog thereof. In HIV positive at-risk subjects one or more anti-retroviral drugs are co-administered.

A method of treatment is disclosed whereby cancer cells are brought into contact with a formulation comprising an inhibitor of tyrosine kinase receptors. The formulation may be comprised of an injectable carrier and two or more tyrosine kinase receptor inhibitors which may be nordihydroguaiarectic acid (NDGA) and doxorubicin.

The invention discloses an application of cytarabine and a proto-oncoprotein c-FOS inhibitor in preparation of a product for treating leukemia. Experiments prove that a synergistic effect exists whencytarabine is combined with nordihydroguaiaretic acid or cytarabine is combined with curcumin to treat leukemia cells, and the drug-resistant reaction of leukemia cells in a cytarabine drug-resistantstrain cell and drug-resistant co-culture medium to cytarabine can be effectively reduced. The invention provides a new approach for overcoming drug resistance reaction for leukemia treatment, and theproto-oncoprotein c-FOS is expected to become a potential target for anti-leukemia treatment, and has very wide application prospect in the medical field.

The invention relates to pharmaceutical lansoprazole composite granules for treating digestive system diseases and belongs to the technical field of medicine. The granules are made from lansoprazole, cane sugar, anhydrous sodium carbonate, croscarmellose sodium, nordihydroguaiaretic acid, 95% ethyl alcohol and talcum powder. The lansoprazole is a new crystal form compound, an X-ray powder diffraction pattern of the lansoprazole measured by using Cu-Ka ray is shown in figure 1, the lansoprazole is different from those reported in the prior art, experiments show that the lansoprazole, the new crystal form compound, provided by the invention has no impurity E, in the lansoprazole, the contents of impurity A and impurity B are evidently decreased and slightly change over storage time, the lansoprazole has good fluidity and evidently improved solubility, and the lansoprazole granules made using the new crystal form compound are good in stability and low in impurity content.

Disclosed are nordihydroguaiaretic acid derivative compounds including various end groups bonded by a carbon atom or heteroatom though a side chain bonded to the respective hydroxy residue O groups by an ether bond or a carbamate bond, pharmaceutical compositions, methods of making them, and methods of using them and kits including them for the treatment of diseases and disorders, in particular, diseases resulting from or associated with a virus infection, such as HIV infection, HPV infection, or HSV infection, an inflammatory disease, such as various types of arthritis and inflammatory bowel diseases, a metabolic disease, such as diabetes, a vascular disease, such as hypertension and macular degeneration, or a proliferative disease, such as diverse types of cancers.

The invention discloses a method for identifying a Larrea extract in cosmetic raw materials and a method for simultaneously and quantitatively detecting nordihydroguaiaretic acid and genkwanin and belongs to the technical field of analysis and detection. The provided method for identifying the Larrea extract in the cosmetic raw materials is characterized in that detection is performed through high performance liquid chromatography, and the detection wavelength is 210 nm. The method for identifying the Larrea extract in the cosmetic raw materials is very simple in pretreatment, high in detection efficiency and wide in application range and is not affected by raw material forms (solid state or liquid state).

A UGT2B inhibitor capable of increasing the bio-availability of a drug, is a compound in a free base or a pharmaceutically acceptable salt form that is selected from the group consisting of: capillarisin, isorhamnetin,β-naphthoflavone, α-naphthoflavone, hesperetin, terpineol, (+)-limonene, β-myrcene, swertiamarin, eriodictyol, cineole, apigenin, baicalin, ursolic acid, isovitexin, lauryl alcohol, puerarin, trans-cinnamaldehyde, 3-phenylpropyl acetate, isoliquritigenin, paeoniflorin, gallic acid, genistein, glycyrrhizin, protocatechuic acid, ethyl myristate, umbelliferone, PEG (Polyethylene glycol) 400, PEG 2000, PEG 4000, Tween 20, Tween 60, Tween 80, BRIJ® 58, BRIJ® 76, Pluronic® F68, Pluronic® F127, and a combination thereof. A UGT2B enhancer capable of enhancing a clearance rate of morphine-like analgesic agents, is a compound in a free base or a pharmaceutically acceptable salt form that is selected from the group consisting of: nordihydroguaiaretic acid, wogonin, trans-cinnamic acid, baicalein, quercetin, daidzein, oleanolic acid, homoorientin, hesperetin, narigin, neohesperidin, (+)-epicatechin, hesperidin, liquiritin, eriodictyol, formononetin, quercitrin, genkwanin, kaempferol, isoquercitrin, (+)-catechin, naringenin, daidzin, (−)-epicatechin, luteolin-7-glucoside, ergosterol, rutin, luteolin, ethyl myristate, apigenin, 3-phenylpropyl acetate, umbelliferone, glycyrrhizin, protocatechuic acid, poncirin, isovitexin, 6-gingerol, cineole, genistein, trans-cinnamaldehyde, and a combination thereof.